Jaypirca (pirtobrutinib) recommended by CHMP for approval in the EU for adults with CLL across all lines of therapy
“Based on the strong results from the BRUIN CLL-313 and CLL-314 studies, we believe Jaypirca has the potential to serve as a meaningful new option for newly diagnosed patients and those who have not yet received a BTK inhibitor,” said Jacob Van Naarden, executive vice president and president of Lilly Oncology. “Thanks to the impact of contemporary CLL treatments, many patients may receive fewer lines of therapy over their lifetime, making treatment choices in earlier lines profoundly important. This CHMP opinion represents a step toward an important global approval for Jaypirca in this indication and reflects our ambition to make Jaypirca available to every CLL patient who may benefit, at any line of therapy. Today, we are on the brink of making that a reality across the European Union as we await the European Commission’s final decision.”
Share:
More News
Dr. Michael GE, CEO of Kelun-Biotech, stated: “We are delighted to see that sac-TMT combined with pembrolizumab has achieved exciting positive results compared with immunotherapy plus chemotherapy in the first-line treatment of patients with PD-L1-negative NSCLC. This ADC plus immunotherapy regimen has previously demonstrated superior efficacy over immunotherapy monotherapy in
“This Fast Track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration,” said Jared Kelly, Chief Executive Officer of Oncolytics. “During that time, we have received Fast Track designation in both metastatic
“These findings build upon the well-established role of KEYTRUDA in endometrial cancer, one of the few cancers with rising incidence rates,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “We are committed to helping women facing this disease by advancing potential treatment options. We thank the
“UB-VV400 is our second VivoVec™ based in vivo CAR T cell program to advance to U.S. clinical trials,” said Luke Walker, M.D., Chief Medical Officer of Umoja Biopharma. “Generating CAR T cells within a patient’s body would have the potential to transform clinical practice. We designed this Phase 1/2 trial